Melinta Therapeutics
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting
06 août 2019 17h04 HE | Melinta Therapeutics
~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) --...
Melinta Therapeutics
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
16 juil. 2019 07h30 HE | Melinta Therapeutics
~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an Increase of 17 Percent Over the First Quarter of 2019 ~ ~ Anticipates Having...
Melinta Therapeutics
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
19 juin 2019 07h30 HE | Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
Melinta Therapeutics
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
09 mai 2019 16h00 HE | Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Melinta Therapeutics
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
07 mai 2019 07h30 HE | Melinta Therapeutics
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019
02 mai 2019 16h30 HE | Melinta Therapeutics
MORRISTOWN, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
08 avr. 2019 07h30 HE | Melinta Therapeutics
MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
13 mars 2019 16h00 HE | Melinta Therapeutics
~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from...
Melinta Therapeutics
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019
05 mars 2019 08h00 HE | Melinta Therapeutics
MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Melinta Therapeutics
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding
25 févr. 2019 08h15 HE | Melinta Therapeutics
– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial...